<p>2025 年 9 月 15 日- 下午 08:02</p>
<p><strong>特斯拉机器人将推动主权 “种子到注射器” 制药基础设施</strong></p>
<p>佛罗里达州劳德代尔堡，2025 年 9 月 15 日（GLOBE NEWSWIRE）-- Bright Green Corporation（OTC: BGXX）宣布与 PharmAGRI Capital Partners 合并，后者是一个与联邦对齐的制药基础设施平台，旨在恢复美国药品制造的主权。该交易将 BGXX 的 DEA 注册、药房执照、审计财务和纳斯达克历史整合到 PharmAGRI，依据在新墨西哥州地区法院监督下提交的重组计划。</p>
<p>即刻生效，Lynn Stockwell 被任命为 PharmAGRI 的首席执行官和董事长。Stockwell 女士将任命一个由她的美国药品收购公司（Drugs Made In America Acquisition Corps）董事组成的新董事会，该系列公司是四家在纳斯达克上市的特殊目的收购公司（SPAC），旨在收购持有 DEA 许可证和符合 FDA 标准的制药企业。收购公司 I 已完成首次公开募股（IPO），II 正在完成 SEC 审查，III 和 IV 正在组建中，以扩大平台的覆盖范围并整合主权生产资产。</p>
<p>PharmAGRI 的垂直整合模式在美国本土完全执行 “种子到注射器” 的药物制造，支持 EB-5 投资者通道、联邦合同获取以及美国制造的受控物质的出口。作为合并的一部分，PharmAGRI 将接管 Bright Green LLC，该公司是 USCIS-EB-5 区域中心的申请者。该区域中心将进行战略重组，以支持主权制药基础设施、机器人部署和符合 EB-5 项目要求的高薪就业创造。</p>
<p>PharmAGRI 已与特斯拉签署意向书（LOI），计划在其自营农场运营、API 合成和处方药制造中部署多达 10,000 台 Optimus 3+ 人形机器人。该部署旨在进行转移控制和 DEA 劳动合规，消除低薪重复性任务，并将大幅减少的劳动力提升到高薪技术角色。它还确保不依赖于无证劳工，用机器人和再培训项目替代历史上被剥削的角色，支持主权就业和工资提升。这些机器人旨在满足所有 DEA 和 FDA 的合规要求，并全天候独立生成全球库存报告，包括任何工作站的标准操作程序。</p>
<p><strong>Stockwell 女士对合并和特斯拉合作的战略愿景进行了评论：</strong></p>
<p>&#34; <em>我们有一个大胆的愿景和一支高度能力的团队，致力于将这一关键制药行业环节本土化。通过果断的承诺和严谨的执行，我们为一个由特斯拉驱动的未来打开了大门——确保 Optimus 3+ 机器人和先进技术的采购与部署，简化我们的运营蓝图。这一举措不仅提升了工资并强化了合法移民实践，还建立了一个主权基础设施，旨在获得联邦合同并为股东提供强劲回报，具备保障美国供应链的能力，符合所有美国人的利益。&#34;</em></p>
<p>PharmAGRI 将很快向美国证券交易委员会（SEC）提交 S-1 注册声明，并将在纳斯达克重新上市之前遵守所有金融行业监管局（FINRA）的要求。拟议的反向股票拆分和优先股发行仍需最终法院和 FINRA 的批准，之后 Lynn Stockwell 将成为合并公司的主要股东，整合治理和资本控制，以执行平台的主权制药使命。</p>
<p>该公司计划在 2025 年底之前完成首次公开募股（IPO），为 PharmAGRI 提供全面市场准入、联邦合同执行和在美国制药基础设施中的战略扩展，同时加强其并购战略，以扩大收入基础并整合主权生产资产。</p>
<p>本新闻稿包含根据 1995 年《私人证券诉讼改革法》“安全港” 条款的 “前瞻性声明”。这些前瞻性声明是在首次发布之日作出的，基于当时的当前预期、估计、预测和假设。诸如 “期望”、“预期”、“应该”、“相信”、“希望”、“目标”、“项目”、“目标”、“估计”、“潜在”、“预测”、“可能”、“将”、“或许”、“能够”、“打算”、“应当” 等词语及其变体或这些词语的否定形式和类似表达，旨在识别这些前瞻性声明。前瞻性声明受到多种风险和不确定性的影响，其中许多因素或情况超出了公司的控制范围。这些前瞻性声明包括但不限于公司实施计划和在公司 EB-5 项目下筹集资金的能力，新任高管、董事和员工可能对公司及其业务和运营结果产生的影响。公司的实际结果可能与所述或暗示的结果有重大差异。</p>
<p>媒体联系：</p>
<p>Info@brightgreen.us</p>
<p>954-870-3099</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVeU9UVTBOeU0zTVRRNE5EUTRJelV3TURFeE9ERXdOQT09?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVeU9UVTBOeU0zTVRRNE5EUTRJelV3TURFeE9ERXdOQT09"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YWFlNTUxOWItYTM4My00MDc3LWJiOTgtZjZiNjBkNDI0NTUxLTUwMDExODEwNC0yMDI1LTA5LTE2LWVu/tiny/Bright-Green-Corporation.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YWFlNTUxOWItYTM4My00MDc3LWJiOTgtZjZiNjBkNDI0NTUxLTUwMDExODEwNC0yMDI1LTA5LTE2LWVu/tiny/Bright-Green-Corporation.png"/></p>

BGXX

<p>Bright Green Corporation 已与 PharmAGRI Capital Partners 合并，Lynn Stockwell 被任命为首席执行官兼董事长。此次合并旨在恢复美国药品制造的主权，并将在法院监督下整合各种许可证和注册。PharmAGRI 计划部署特斯拉机器人进行药品制造，以增强合规性并创造高薪职位。该公司打算在 2025 年底之前申请纳斯达克重新上市并完成首次公开募股，重点关注联邦合同并扩展美国制药基础设施</p>

<p>09/15/2025 - 08:02 PM</p>
<div class="lb-trans"><p>2025 年 9 月 15 日- 下午 08:02</p>
</div><p><strong>Tesla Robotics to Power Sovereign “Seed to Syringe” Pharmaceutical Infrastructure</strong></p>
<div class="lb-trans"><p><strong>特斯拉机器人将推动主权 “种子到注射器” 制药基础设施</strong></p>
</div><p>Fort Lauderdale, FL, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Bright Green Corporation (OTC: BGXX) has announced its merger with PharmAGRI Capital Partners, a federally aligned pharmaceutical infrastructure platform architected to restore U.S. drug manufacturing sovereignty. The transaction consolidates BGXX’s DEA registrations, Board of Pharmacy licensure, audited financials, and Nasdaq history into PharmAGRI under a court-supervised restructuring plan filed in the District of New Mexico.</p>
<div class="lb-trans"><p>佛罗里达州劳德代尔堡，2025 年 9 月 15 日（GLOBE NEWSWIRE）-- Bright Green Corporation（OTC: BGXX）宣布与 PharmAGRI Capital Partners 合并，后者是一个与联邦对齐的制药基础设施平台，旨在恢复美国药品制造的主权。该交易将 BGXX 的 DEA 注册、药房执照、审计财务和纳斯达克历史整合到 PharmAGRI，依据在新墨西哥州地区法院监督下提交的重组计划。</p>
</div><p>Effective immediately, Lynn Stockwell has been appointed Chief Executive Officer and Chairwoman of PharmAGRI. Ms. Stockwell will appoint a new board composed of directors from her Drugs Made In America Acquisition Corps—a series of four Nasdaq-listed special purpose acquisition companies (SPACs) formed to acquire DEA-licensed and FDA-compliant pharmaceutical businesses. Acquisition Corps I has completed an IPO and II is completing the SEC review, with Corps III and IV in formation to expand the platform’s reach and consolidate sovereign production assets.</p>
<div class="lb-trans"><p>即刻生效，Lynn Stockwell 被任命为 PharmAGRI 的首席执行官和董事长。Stockwell 女士将任命一个由她的美国药品收购公司（Drugs Made In America Acquisition Corps）董事组成的新董事会，该系列公司是四家在纳斯达克上市的特殊目的收购公司（SPAC），旨在收购持有 DEA 许可证和符合 FDA 标准的制药企业。收购公司 I 已完成首次公开募股（IPO），II 正在完成 SEC 审查，III 和 IV 正在组建中，以扩大平台的覆盖范围并整合主权生产资产。</p>
</div><p>PharmAGRI’s vertically integrated model executes “seed to syringe” drug manufacturing entirely on American soil, supporting EB-5 investor pathways, federal contract capture, and export of U.S.-manufactured controlled substances. As part of the merger, PharmAGRI will assume control of Bright Green LLC, a USCIS- EB-5 Regional Center applicant. The Regional Center will undergo a strategic realignment to support sovereign pharmaceutical infrastructure, robotics deployment, and high-wage job creation consistent with EB-5 program requirements.</p>
<div class="lb-trans"><p>PharmAGRI 的垂直整合模式在美国本土完全执行 “种子到注射器” 的药物制造，支持 EB-5 投资者通道、联邦合同获取以及美国制造的受控物质的出口。作为合并的一部分，PharmAGRI 将接管 Bright Green LLC，该公司是 USCIS-EB-5 区域中心的申请者。该区域中心将进行战略重组，以支持主权制药基础设施、机器人部署和符合 EB-5 项目要求的高薪就业创造。</p>
</div><p>PharmAGRI has executed a Letter of Intent (LOI) with Tesla to deploy up to 10,000 Optimus 3+ humanoid robotics across its owner-operator farm operations, API synthesis, and prescription drug manufacturing. The deployment is engineered for diversion control and DEA labor compliance, eliminating low-wage repetitive tasks and elevating the substantially reduced labor force into high-wage technical roles. It also ensures no reliance on undocumented labor, replacing historically exploited roles with robotics and retraining programs that support sovereign employment and wage elevation. The robotic are designed to meet all DEA and FDA compliance and are audit ready around-the-clock independently generating reports on global inventory, including standard operating procedures at any of the work stations.</p>
<div class="lb-trans"><p>PharmAGRI 已与特斯拉签署意向书（LOI），计划在其自营农场运营、API 合成和处方药制造中部署多达 10,000 台 Optimus 3+ 人形机器人。该部署旨在进行转移控制和 DEA 劳动合规，消除低薪重复性任务，并将大幅减少的劳动力提升到高薪技术角色。它还确保不依赖于无证劳工，用机器人和再培训项目替代历史上被剥削的角色，支持主权就业和工资提升。这些机器人旨在满足所有 DEA 和 FDA 的合规要求，并全天候独立生成全球库存报告，包括任何工作站的标准操作程序。</p>
</div><p><strong>Ms. Stockwell commented on the strategic vision behind the merger and Tesla partnership:</strong></p>
<div class="lb-trans"><p><strong>Stockwell 女士对合并和特斯拉合作的战略愿景进行了评论：</strong></p>
</div><p>&#34; <em>We have a bold vision and a highly capable team committed to on-shoring this critical segment of the pharmaceutical industry. Through decisive commitments and disciplined execution, we’ve opened the door to a future powered by Tesla—securing procurement and deployment of Optimus 3+ robotics and advanced technologies that streamline our operational blueprint. This initiative not only elevates wages and reinforces lawful immigration practices, but establishes a sovereign infrastructure positioned to earn federal contracts and deliver strong returns to shareholders with conviction, and capability to secure the U.S. supply chain in the interest of all Americans.&#34;</em></p>
<div class="lb-trans"><p>&#34; <em>我们有一个大胆的愿景和一支高度能力的团队，致力于将这一关键制药行业环节本土化。通过果断的承诺和严谨的执行，我们为一个由特斯拉驱动的未来打开了大门——确保 Optimus 3+ 机器人和先进技术的采购与部署，简化我们的运营蓝图。这一举措不仅提升了工资并强化了合法移民实践，还建立了一个主权基础设施，旨在获得联邦合同并为股东提供强劲回报，具备保障美国供应链的能力，符合所有美国人的利益。&#34;</em></p>
</div><p>PharmAGRI will soon file a Form S-1 registration statement with the U.S. Securities and Exchange Commission (SEC) and will comply with all Financial Industry Regulatory Authority (FINRA) requirements prior to its Nasdaq relisting. The proposed reverse stock split and preferred share issuance remain subject to final court and FINRA approval, after which Lynn Stockwell will become the majority shareholder of the combined company, consolidating governance and capital control to execute the platform’s sovereign pharmaceutical mission.</p>
<div class="lb-trans"><p>PharmAGRI 将很快向美国证券交易委员会（SEC）提交 S-1 注册声明，并将在纳斯达克重新上市之前遵守所有金融行业监管局（FINRA）的要求。拟议的反向股票拆分和优先股发行仍需最终法院和 FINRA 的批准，之后 Lynn Stockwell 将成为合并公司的主要股东，整合治理和资本控制，以执行平台的主权制药使命。</p>
</div><p>The company intends to complete its initial public offering (IPO) before year-end 2025, positioning PharmAGRI for full market access, federal contract execution, and strategic expansion across U.S. pharmaceutical infrastructure—while strengthening its mergers and acquisitions strategy to grow the revenue base and consolidate sovereign production assets.</p>
<div class="lb-trans"><p>该公司计划在 2025 年底之前完成首次公开募股（IPO），为 PharmAGRI 提供全面市场准入、联邦合同执行和在美国制药基础设施中的战略扩展，同时加强其并购战略，以扩大收入基础并整合主权生产资产。</p>
</div><p>This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made as of the date they were first issued and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management as of such date. Words such as “expect,” “anticipate,” “should,” “believe,” “hope,” “target,” “project,” “goals,” “estimate,” “potential,” “predict,” “may,” “will,” “might,” “could,” “intend,” “shall” and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond the Company’s control. Such forward looking statements include, but are not limited to, the ability of the Company to implement the Plan and raise funds under the Company’s EB-5 program, the impact that new officers, directors and employees may have on the Company and the Company’s business and results of operations. The Company’s actual results could differ materially from those stated or implied</p>
<div class="lb-trans"><p>本新闻稿包含根据 1995 年《私人证券诉讼改革法》“安全港” 条款的 “前瞻性声明”。这些前瞻性声明是在首次发布之日作出的，基于当时的当前预期、估计、预测和假设。诸如 “期望”、“预期”、“应该”、“相信”、“希望”、“目标”、“项目”、“目标”、“估计”、“潜在”、“预测”、“可能”、“将”、“或许”、“能够”、“打算”、“应当” 等词语及其变体或这些词语的否定形式和类似表达，旨在识别这些前瞻性声明。前瞻性声明受到多种风险和不确定性的影响，其中许多因素或情况超出了公司的控制范围。这些前瞻性声明包括但不限于公司实施计划和在公司 EB-5 项目下筹集资金的能力，新任高管、董事和员工可能对公司及其业务和运营结果产生的影响。公司的实际结果可能与所述或暗示的结果有重大差异。</p>
</div><p>Media Contact:</p>
<div class="lb-trans"><p>媒体联系：</p>
</div><p>Info@brightgreen.us</p>
<div class="lb-trans"><p>Info@brightgreen.us</p>
</div><p>954-870-3099</p>
<div class="lb-trans"><p>954-870-3099</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVeU9UVTBOeU0zTVRRNE5EUTRJelV3TURFeE9ERXdOQT09" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTUyOTU0NyM3MTQ4NDQ4IzUwMDExODEwNA=="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YWFlNTUxOWItYTM4My00MDc3LWJiOTgtZjZiNjBkNDI0NTUxLTUwMDExODEwNC0yMDI1LTA5LTE2LWVu/tiny/Bright-Green-Corporation.png" alt="" original-src="https://ml.globenewswire.com/media/YWFlNTUxOWItYTM4My00MDc3LWJiOTgtZjZiNjBkNDI0NTUxLTUwMDExODEwNC0yMDI1LTA5LTE2LWVu/tiny/Bright-Green-Corporation.png"/></p>

Bright Green Corporation 与 PharmAGRI Capital Partners 合并；Lynn Stockwell 被任命为首席执行官兼董事会主席 | BGXX 股票新闻